Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

Tremendous advances in our understanding of pathogenesis of amyotrophic lateral
sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …

The recent approval of edaravone has provided an intravenous option to treat amyotrophic
lateral sclerosis (ALS) in addition to the existing oral agent, riluzole. The present work was …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …

Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease
that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It …

Amyotrophic lateral sclerosis (ALS) is the commonest form of motor neuron disease and is a
fatal, degenerative, multisystem disorder affecting upper and/or lower motor neurons in the …

Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease of the
human motor system. Aetiological mechanisms implicated in the development of ALS have …